Continuous Glucose Monitoring in Hospitalized Patients with Type 2 Diabetes: A Step Forward in Inpatient Glycemic Control.

IF 3.7 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Endocrine Practice Pub Date : 2025-02-13 DOI:10.1016/j.eprac.2025.02.007

Alejandra Rivas-Montenegro, Roberto Añez-Ramos, Pastor Galdón-Sanz, Olga González-Albarrán

{"title":"Continuous Glucose Monitoring in Hospitalized Patients with Type 2 Diabetes: A Step Forward in Inpatient Glycemic Control.","authors":"Alejandra Rivas-Montenegro, Roberto Añez-Ramos, Pastor Galdón-Sanz, Olga González-Albarrán","doi":"10.1016/j.eprac.2025.02.007","DOIUrl":null,"url":null,"abstract":"Objectives: To determine the effect and safety of Continuous Glucose Monitoring (CGM) use in glycemic control compared to standard approach in hospitalized patients with Type 2 Diabetes (T2D).Methods: This was a pilot randomized controlled clinical trial enrolled 37 hospitalized patients with T2D admitted in medical and surgical wards. All patients used CGM (Abbott FreeStyle2 or FreeStyle3) and concomitantly 6-point point of care glucose (POCG). In group A (n=19), daily CGM profiles, alarms, and trend arrows were considered for glycemic therapeutic decisions and in group B (n=18) were based on POCG. Primary outcomes included the difference in time in range (TIR) 70-180 mg/dL, hospital glycemia risk index (GRI), time below range (TBR) measured as the percentage below 70 mg/dL and below 54 mg/dL, and time above range (TAR) measured as the percentage above 180 mg/dL and above 250 mg/dL.Results: TIR was higher in group A: 78.26±10.83% vs. 67.39±19.13% p=0.04. TAR level 1 in group A: 14.37±8.33% vs. group B: 23.28±16.62% p=0.04. Asymptomatic hypoglycemic events were more detected by CGM-group (1.65±2.03 vs. 0.31±0.60 p=0.01). Overall MARD: 14.7%. DTS Error Grid: 69.5% zone A and 29.3% zone B.Conclusions: The implementation of CGM in hospitals could represent a significant advancement in diabetes management, offering a more comprehensive and dynamic approach to monitoring glucose levels. Further research is needed to explore the long-term impacts of CGM on clinical outcomes and to optimize its integration into hospital protocols.","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.eprac.2025.02.007","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: To determine the effect and safety of Continuous Glucose Monitoring (CGM) use in glycemic control compared to standard approach in hospitalized patients with Type 2 Diabetes (T2D).

Methods: This was a pilot randomized controlled clinical trial enrolled 37 hospitalized patients with T2D admitted in medical and surgical wards. All patients used CGM (Abbott FreeStyle2 or FreeStyle3) and concomitantly 6-point point of care glucose (POCG). In group A (n=19), daily CGM profiles, alarms, and trend arrows were considered for glycemic therapeutic decisions and in group B (n=18) were based on POCG. Primary outcomes included the difference in time in range (TIR) 70-180 mg/dL, hospital glycemia risk index (GRI), time below range (TBR) measured as the percentage below 70 mg/dL and below 54 mg/dL, and time above range (TAR) measured as the percentage above 180 mg/dL and above 250 mg/dL.

Results: TIR was higher in group A: 78.26±10.83% vs. 67.39±19.13% p=0.04. TAR level 1 in group A: 14.37±8.33% vs. group B: 23.28±16.62% p=0.04. Asymptomatic hypoglycemic events were more detected by CGM-group (1.65±2.03 vs. 0.31±0.60 p=0.01). Overall MARD: 14.7%. DTS Error Grid: 69.5% zone A and 29.3% zone B.

Conclusions: The implementation of CGM in hospitals could represent a significant advancement in diabetes management, offering a more comprehensive and dynamic approach to monitoring glucose levels. Further research is needed to explore the long-term impacts of CGM on clinical outcomes and to optimize its integration into hospital protocols.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Endocrine Practice ENDOCRINOLOGY & METABOLISM-

CiteScore

7.60

自引率

2.40%

发文量

546

审稿时长

41 days

期刊介绍： Endocrine Practice (ISSN: 1530-891X), a peer-reviewed journal published twelve times a year, is the official journal of the American Association of Clinical Endocrinologists (AACE). The primary mission of Endocrine Practice is to enhance the health care of patients with endocrine diseases through continuing education of practicing endocrinologists.